Currently, the number of SHP2 inhibitors are under clinical trials for tumor-targeted therapies [34] and NAC as a ROS scavenger has been reported to improve traumatic brain injury in human trials [35], suggesting an implication for their therapeutic application as an alternative to E2 for bone loss in human. This evidence concerns the gene PTPN11 and neoplasm.